Edwards Lifesciences (EW)

=== SEC Form 4 — Statement of Changes in Beneficial Ownership === Document Type: 4 Period of Report: 2026-09-11 10b5-1 Pre-arranged Plan: Yes --- Issuer --- Name: Edwards Lifesciences Corp (EW) CIK: 0001099800 --- Reporting Owner --- Name: Lippis Daniel J. CIK: 0002004380 Role: Officer (CVP, TAVR) --- Non-Derivative Transactions --- [Transaction #1] Security: Common Stock Date: 2026-09-11 | Code: M (Exercise of derivative) Shares: +619 | Price: $72.68 Total Value: $44,988.92 Shares Owned After: 40,652.9103 | Ownership: D (Direct) Footnotes: [F1] The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. [Transaction #2] Security: Common Stock Date: 2026-09-11 | Code: S (Open market sale) Shares: -619 | Price: $87.51 Total Value: $54,168.69 Shares Owned After: 40,033.9103 | Ownership: D (Direct) Footnotes: [F1] The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. --- Derivative Transactions --- [Transaction #1] Security: Employee Stock Option (Right to Acquire) Date: 2026-09-11 | Code: M (Exercise of derivative) Shares: -619 | Price: $0.00 Exercise Price: $72.68 Exercisable: N/A | Expires: 2027-05-06 Shares Owned After: 3,714 | Ownership: D (Direct) --- Footnotes (Complete Index) --- F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. --- Signature --- /s/ Linda J. Park, Attorney-in-Fact (2026-09-11)